EFDID: 248082EFD: View Filing

Issuer: Bellerophon Therapeutics, Inc. (0001600132) - D

Accession: 0001600132-17-000114 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001600132
  • Entity Name:
    Bellerophon Therapeutics, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    DELAWARE
  • Year of Inc:
    Within 5 years (2013)
  • Address:
    184 LIBERTY CORNER ROAD, SUITE 302
    WARREN, NJ 07059
  • Persons:
    Related Persons 15
    Fabian Tenenbaum
    Executive Officer, Director
    Jonathan M. Peacock
    Director
    Naseem P. Amin
    Director
    Scott P. Bruder
    Director
    Mary Ann Cloyd
    Director
    Jens Luehring
    Director
    Andre V. Moura
    Director
    Daniel Tasse
    Director
    Adam B. Weinstein
    Director
    Peter Fernandes
    Executive Officer
    Deborah A. Quinn
    Executive Officer
    Martin Dekker
    Executive Officer
    Amy Edmonds
    Executive Officer
    Parag Shah
    Executive Officer
    Megan Schoeps
    Executive Officer
EDGAR: Offering Information
  • Accession Date:
    10/11/2017
  • First Sale Date:
    09/29/2017
  • Offering Amount:
    $23,437,050
  • Amount Sold:
    $23,437,050
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
EFD: Current State Notices
View Notices

Notices found in EFD

Filed:CA, NJ
EDGAR: Sales Compensation Recipient Information
RecipientCRDBroker DealerBD CRDStates
Theodore Wang 2786005 Angel Pond Capital LLC 287761 CA, NJ, NY
EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Bellerophon Therapeutics, Inc./s/ Fabian TenenbaumFabian TenenbaumChief Executive Officer2017-10-09